Skip to content
  • About
  • Team
  • Clinical Studies
  • Investing
  • Press
  • Contact
Menu
  • About
  • Team
  • Clinical Studies
  • Investing
  • Press
  • Contact
  • About
  • Team
  • Clinical Studies
  • Investing
  • Press
  • Contact
Menu
  • About
  • Team
  • Clinical Studies
  • Investing
  • Press
  • Contact

Accelerated access to safe and effective psychedelic-assisted therapy.

Albert Labs is the first psychedelic company leveraging Real World Evidence Studies to enhance patient care by accelerating access to psychedelic therapy in a hospital setting for niche indications with urgent and high unmet needs.

Investor Portal Access

Access the Albert Labs Investor Portal. Here you can find all the documents you may require for due diligence. 

Investor portal
12/20/2020

Investing Summary

A comprehensive & concise summary of the Albert Labs investment opportunity.
12/20/2020

Investor Presentation

The full copy of the Albert Labs investment presentation.

Corporate Highlights

Alberts Labs’ mission to ensure accelerated access to safe and effective psychedelic-assisted therapy for patients with urgent, unmet needs.

First psychedelics company leveraging established, accelerated pathways to psychedelic-assisted therapies for patients with urgent, unmet needs across european and other international healthcare structures.

Albert Labs is a collaboration between leading academic research institutions and medical centers to swiftly provide access for patients whilst collecting data and obtaining reimbursement.

Developing scalable solutions to generate effectiveness data and access existing patient pools within world leading research and clinical networks for established niche indications.

Starting with cancer related anxiety & depression in end of life patients and moving into broader mental health indications – patients cannot wait 5+ years and big pharma are not developing solutions.

… View more in the Investing Summary

Downloads

Media Summary

Latest corporate tear sheet

Latest Press Release

.pdf copy of our latest Press Release

Key Personnel

Meet the Albert Labs team

Key research

Summary of key research publications

RSS Feed

Subscribe via RSS here.

Let us tell you more.

We will email you to start the conversation.

accelerated access to safe and effective psychedelic-assisted therapy for patients with urgent, unmet needs.

Facebook
Twitter
Linkedin
Youtube
Envelope
  • Legal Disclaimer
  • Privacy Policy
  • Modern Slavery Statement
  • Cookie Policy
Menu
  • Legal Disclaimer
  • Privacy Policy
  • Modern Slavery Statement
  • Cookie Policy
  • About
  • Team
  • Clinical Studies
  • Investing
  • Press
  • Contact
Menu
  • About
  • Team
  • Clinical Studies
  • Investing
  • Press
  • Contact

© 2021 Albert Labs. All Rights Reserved

Canada – 6996, Merritt Ave, Burnaby, BC, V5J 4R6 | United kingdom – 21 Marylebone High St, Unit 6, Marylebone, London W1U 4PE

By completing this form you agree to our privacy policy. You will be sent corporate updates and further details including how to invest in Albert Labs.

By completing this form you agree to our privacy policy. You will be sent corporate updates and further details including how to invest in Albert Labs.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok